Breaking News - The Fly

Open Search

TRDA

Entrada Therapeutics

$

()

Entrada Therapeutics expects cash to fund requirements through 2Q26

TRDA

3/13/2024 - 07:08am

Entrada Therapeutics reports Q4 EPS (29c), consensus (17c)

TRDA

3/13/2024 - 07:08am

Entrada Therapeutics initiated with an Outperform at Oppenheimer

TRDA , VRTX

1/4/2024 - 16:07pm

Entrada Therapeutics promotes Dowden to President

TRDA

1/3/2024 - 07:04am

Entrada Therapeutics price target lowered to $20 from $25 at H.C. Wainwright

TRDA

11/27/2023 - 06:07am

Entrada completes dosing for first, second cohorts Phase 1 ENTR-601-44-101

TRDA

11/22/2023 - 07:01am

Entrada Therapeutics expects cash to fund requirements through 2025

TRDA

11/7/2023 - 07:12am

Entrada Therapeutics reports Q3 EPS $1.02, consensus (74c)

TRDA

11/7/2023 - 07:12am

Entrada announces first patient dosed in Phase 1 trial of ENTR-601-44

TRDA

9/21/2023 - 07:03am

Entrada Therapeutics awards funding to non-profit organizations

TRDA

9/7/2023 - 07:04am

Entrada Therapeutics appoints Chapman to its board of directors

TRDA

8/10/2023 - 07:22am

Entrada Therapeutics reports Q2 EPS (78c), consensus (69c)

TRDA

8/8/2023 - 07:18am

Entrada receives authorization in the UK for Phase I trial of ENTR-601-44

TRDA

8/1/2023 - 07:21am

Entrada Therapeutics expects cash runway to last into H2 of 2025

TRDA

5/10/2023 - 07:11am

Entrada Therapeutics reports Q1 EPS (21c) vs (69c) last year

TRDA

5/10/2023 - 07:10am